Skip navigation
MOST POPULAR RELATED TAGS
  • TOPICS
  • SECTORS
  • COMPANIES

MAD MONEY FEATURES

Podcasts PODCASTS
Watch the Lightning Round whenever and wherever you want.




Widget OFFICIAL MAD MONEY WIDGET
Grab this all-in-one application and get recaps of the show sent right to your desktop or blog.




Soundboard CRAMERS SOUNDBOARD
Admit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.




Mad Money PhotosCHECK OUT OUR PHOTOS
Check out Cramer on set, back to school, behind the scenes and more.




ShopSHOP FOR MAD MERCHANDISE
Buy Cramer books, bobbleheads and other Mad Money merchandise.




Ringtones RING TONES
Pick up the phone! It's Cramer! New Mad Money sounds for your cell phone.




Mobile AlertTEXT MESSAGE ALERT
Mad Money's mobile. Get show highlights sent to your phone.







Text Size

President Obama’s Medicare plans did a number on health-care stocks these past couple of weeks. Drug companies like Eli Lilly [LLY  Loading...      ()   ] and Merck [MRK  Loading...      ()   ], as well as medical-device makers like St. Jude [STJ  Loading...      ()   ], were all under pressure because Wall Street feared the worst. This once-classic recession-resistant sector – medicine is needed regardless of the economic situation – fell out of favor almost immediately.

But not every stock deserved such harsh treatment. That’s because there are at least a couple of companies that deal in health-care staples rather than expensive drugs or MRI machines. Becton Dickinson [BDX  Loading...      ()   ] and Baxter [BAX  Loading...      ()   ] get 58% and 37%, respectively, of their revenues from basic hospital supplies. Think lost-cost consumable items that are constantly replenished. They’re the kind of medical spending about which Obama’s not concerned

Cramer called BDX and BAX the Wal-Marts [WMT  Loading...      ()   ] of health care. They sell the bare necessities. Products that even the most cash-strapped hospitals will keep buying. Fifty-three percent of Becton Dickinson’s sales comes from hypodermic syringes and needles, scalpels and prefillable drug delivery systems. Thirty percent comes from diagnostics. Only 6% of BDX is exposed to equipment sales that could suffer during an Obama administration. So it would be hard for the president to hurt this company.

Baxter’s biosciences unit, which accounts for 44% of sales, makes treatments for hemophilia, biopharmaceuticals for immune deficiencies and cancer, vaccines and biosurgery equipment. These are largely in-hospital treatments, a marked difference from the high-cost drugs Obama is targeting. Baxter also runs a medial-delivery unit that makes IV solutions, critical-care injectable drugs and products for anesthesia, nutrition and oncology. That’s worth 37% of sales, and the renal care division accounts for 19%. The dialysis products made by that latter division are yet another health-care area that Obama won’t touch.

Both companies recently reported better-than-expected quarters, though BDX was light on revenues, which killed the stock’s momentum. But Baxter and Becton Dickinson are looking forward to a good 2009.

Right now BDX and BAX are trading at their historical multiple lows – what Cramer called the Obama discount – giving investors a great entry point. And the consistent, steady growth these companies offer couldn’t come at a better time.





Cramer's charitable trust owns Wal-Mart.

Questions for Cramer?

Questions, comments, suggestions for the Mad Money website?

© 2009 CNBC, Inc. All Rights Reserved

Tools:
PrintEmailAdd This share icon
Next Post
  • digg share
ADD COMMENTS
Remaining characters


Current DateTime: 03:14:50 24 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 12:00:49 24 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 04:59:27 24 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 12:00:49 24 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters